The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytoametry

Cytometry Part A

Volumn 85, Issue 1, 2014, Pages 78-87

  Watson, Maria ^a   Chow, Sue ^a   Barsyte, Dalia ^a   Arrowsmith, Cheryl ^a   Shankey, T Vincent ^b   Minden, Mark ^a   Hedley, David ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BECKMAN COULTER INC   (United States)

Author keywords

Drug treatment; Epigenetics; Flow cytoametry; Histone; Leukemia

Indexed keywords

HISTONE; HISTONE DEMETHYLASE;

ARTICLE; BLOOD; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA METHYLATION; DRUG THERAPY; EPIGENETICS; FLOW CYTOAMETRY; FLOW CYTOMETRY; GENETIC EPIGENESIS; GENETICS; HUMAN; LEUKEMIA; METHODOLOGY; PATHOLOGY;

DRUG TREATMENT; EPIGENETICS; FLOW CYTOAMETRY; HISTONE; LEUKEMIA;

CELL DIFFERENTIATION; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FLOW CYTOMETRY; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LEUKEMIA;

EID: 84890857374     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22344     Document Type: Article

References (27)

1. Kreso A, O'Brien CA, van GP, Gan OI, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;339:543-548.
2. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
3. Fathi AT, bdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol 2012;2012:469592.
4. Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC, Kung HF. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 2013;331:1-10.
5. bdel-Wahab O, Adli M, Lafave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193.
6. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
7. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20:66-78.
8. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008;14:355-368.
9. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-833.
10. Scholz B, Marschalek R. Epigenetics and blood disorders. Br J Haematol 2012;158:307-322.
11. Shih AH, bdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599-612.
12. Sandoval J, Esteller M. Cancer epigenomics: Beyond genomics. Curr Opin Genet Dev 2012;22:50-55.
13. Verma M. Epigenetic biomarkers in cancer epidemiology. Methods Mol Biol 2012;863:467-480.
14. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, MacNevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013; Epub ahead of print.
15. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-112.
16. Darzynkiewicz Z, Crissman H, Jacobberger JW. Cytometry of the cell cycle: Cycling through history. Cytometry Part A 2004;58A:21-32.
17. Huang X, Halicka HD, Traganos F, Tanaka T, Kurose A, Darzynkiewicz Z. Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif 2005;38:223-243.
18. Klokov D, MacPhail SM, Banath JP, Byrne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 2006;80:223-229.
19. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, Varagnolo L, Müller AM, Karas M, Dingermann T, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 2011;25:135-144.
20. Obier N, Muller AM. Chromatin flow cytoametry identifies changes in epigenetic cell states. Cells Tissues Organs 2010;191:167-174.
21. Chen H, Yan Y, Davidson TL, Shinkai Y, Costa M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. Cancer Res 2006;15;66:9009-9016.
22. Lee SH, Kim J, Kim WH, Lee YM. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene 2009;15;28:184-194.
23. Bruno S, Gorczyca W, Darzynkiewicz Z. Effect of ionic strength in immunocytoachemical detection of the proliferation associated nuclear antigens p120, PCNA, and the protein reacting with Ki-67 antibody. Cytometry 1992;13:496-501.
24. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytoametry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry Part A 2005;67A:4-17.
25. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007;21:49-54.
26. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 2008;215:175-183.
27. Chung EJ, Lee S, Sausville EA, Ryan Q, Karp JE, Gojo I, Telford WG, Lee MJ, Kong HS, Trepel JB. Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytoametry. Ann Clin Lab Sci 2005;35:397-406.